Hu L, Han J, Wang H, Cheng Z, Lv C, Liu D
Nat Commun. 2025; 16(1):1260.
PMID: 39893181
PMC: 11787337.
DOI: 10.1038/s41467-025-56655-7.
Wang X, Cheng X, Li Z, Ma S, Zhang H, Chen Z
bioRxiv. 2025; .
PMID: 39763781
PMC: 11702641.
DOI: 10.1101/2024.12.17.628899.
Yang X, Zhu P, Gui J
Int J Mol Sci. 2024; 25(15).
PMID: 39125884
PMC: 11313136.
DOI: 10.3390/ijms25158314.
Li T, Li S, Kang Y, Zhou J, Yi M
J Transl Med. 2024; 22(1):749.
PMID: 39118151
PMC: 11312220.
DOI: 10.1186/s12967-024-05570-4.
Wu X, Yang J, Zhang J, Song Y
MedComm (2020). 2024; 5(7):e639.
PMID: 38974714
PMC: 11224995.
DOI: 10.1002/mco2.639.
Breaking genetic shackles: The advance of base editing in genetic disorder treatment.
Xu F, Zheng C, Xu W, Zhang S, Liu S, Chen X
Front Pharmacol. 2024; 15:1364135.
PMID: 38510648
PMC: 10953296.
DOI: 10.3389/fphar.2024.1364135.
CRISPR technologies for genome, epigenome and transcriptome editing.
Villiger L, Joung J, Koblan L, Weissman J, Abudayyeh O, Gootenberg J
Nat Rev Mol Cell Biol. 2024; 25(6):464-487.
PMID: 38308006
DOI: 10.1038/s41580-023-00697-6.
Precise genome editing with base editors.
Liu H, Zhu Y, Li M, Gu Z
Med Rev (2021). 2023; 3(1):75-84.
PMID: 37724105
PMC: 10471085.
DOI: 10.1515/mr-2022-0044.
Base editing enables duplex point mutagenesis in at the price of numerous off-target mutations.
Seys F, Humphreys C, Tomi-Andrino C, Li Q, Millat T, Yang S
Front Bioeng Biotechnol. 2023; 11:1211197.
PMID: 37496853
PMC: 10366002.
DOI: 10.3389/fbioe.2023.1211197.
Base editor screens for in situ mutational scanning at scale.
Lue N, Liau B
Mol Cell. 2023; 83(13):2167-2187.
PMID: 37390819
PMC: 10330937.
DOI: 10.1016/j.molcel.2023.06.009.
Base Editing and Prime Editing: Potential Therapeutic Options for Rare and Common Diseases.
Testa L, Musunuru K
BioDrugs. 2023; 37(4):453-462.
PMID: 37314680
DOI: 10.1007/s40259-023-00610-9.
Strategies for precise gene edits in mammalian cells.
Fichter K, Setayesh T, Malik P
Mol Ther Nucleic Acids. 2023; 32:536-552.
PMID: 37215153
PMC: 10192336.
DOI: 10.1016/j.omtn.2023.04.012.
Advances in CRISPR/Cas gene therapy for inborn errors of immunity.
Liu X, Li G, Liu Y, Zhou F, Huang X, Li K
Front Immunol. 2023; 14:1111777.
PMID: 37051232
PMC: 10083256.
DOI: 10.3389/fimmu.2023.1111777.
Recent advances in therapeutic CRISPR-Cas9 genome editing: mechanisms and applications.
Zhou L, Yao S
Mol Biomed. 2023; 4(1):10.
PMID: 37027099
PMC: 10080534.
DOI: 10.1186/s43556-023-00115-5.
Development of a versatile nuclease prime editor with upgraded precision.
Li X, Zhang G, Huang S, Liu Y, Tang J, Zhong M
Nat Commun. 2023; 14(1):305.
PMID: 36658146
PMC: 9852468.
DOI: 10.1038/s41467-023-35870-0.
Improvements of nuclease and nickase gene modification techniques for the treatment of genetic diseases.
Lu Y, Happi Mbakam C, Song B, BenDavid E, Tremblay J
Front Genome Ed. 2022; 4:892769.
PMID: 35958050
PMC: 9360573.
DOI: 10.3389/fgeed.2022.892769.
Systematic Exploration of Optimized Base Editing gRNA Design and Pleiotropic Effects with BExplorer.
Zhang G, Zhu C, Chen X, Yan J, Xue D, Wei Z
Genomics Proteomics Bioinformatics. 2022; 21(6):1237-1245.
PMID: 35792260
PMC: 11082405.
DOI: 10.1016/j.gpb.2022.06.005.
CRISPR-mediated protein-tagging signal amplification systems for efficient transcriptional activation and repression in Saccharomyces cerevisiae.
Zhai H, Cui L, Xiong Z, Qi Q, Hou J
Nucleic Acids Res. 2022; 50(10):5988-6000.
PMID: 35641106
PMC: 9178002.
DOI: 10.1093/nar/gkac463.
A universal strategy for AAV delivery of base editors to correct genetic point mutations in neonatal PKU mice.
Zhou L, Su J, Long J, Tao R, Tang W, Qin F
Mol Ther Methods Clin Dev. 2022; 24:230-240.
PMID: 35141352
PMC: 8803597.
DOI: 10.1016/j.omtm.2022.01.001.
Base Editing of Somatic Cells Using CRISPR-Cas9 in .
Marr E, Potter C
CRISPR J. 2021; 4(6):836-845.
PMID: 34813372
PMC: 8744452.
DOI: 10.1089/crispr.2021.0062.